Cullen Investment Group LTD. Decreases Position in ICON Public Limited (NASDAQ:ICLR)

Cullen Investment Group LTD. trimmed its position in shares of ICON Public Limited (NASDAQ:ICLR) by 1.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,080 shares of the medical research company’s stock after selling 84 shares during the period. Cullen Investment Group LTD.’s holdings in ICON Public were worth $1,460,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Liontrust Investment Partners LLP grew its stake in ICON Public by 19.5% in the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock valued at $37,531,000 after buying an additional 19,546 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its stake in shares of ICON Public by 15.9% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after purchasing an additional 13,163 shares during the period. State of Tennessee Treasury Department lifted its holdings in ICON Public by 4.9% during the 4th quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company’s stock worth $44,101,000 after purchasing an additional 7,270 shares in the last quarter. SkyView Investment Advisors LLC purchased a new stake in ICON Public during the 1st quarter worth about $1,021,000. Finally, Crestwood Advisors Group LLC bought a new position in ICON Public in the 2nd quarter worth about $288,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ICLR has been the subject of a number of analyst reports. Truist Financial restated a “buy” rating and issued a $383.00 price objective on shares of ICON Public in a research report on Wednesday, September 11th. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. StockNews.com cut shares of ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Robert W. Baird dropped their price objective on ICON Public from $368.00 to $340.00 and set an “outperform” rating for the company in a research note on Friday, September 20th. Finally, Leerink Partners initiated coverage on ICON Public in a research note on Wednesday, September 18th. They issued an “outperform” rating and a $379.00 target price on the stock. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ICON Public has a consensus rating of “Buy” and an average target price of $351.60.

ICON Public Trading Up 0.1 %

Shares of ICLR traded up $0.36 during mid-day trading on Friday, reaching $293.54. The company’s stock had a trading volume of 482,725 shares, compared to its average volume of 576,656. ICON Public Limited has a 52 week low of $221.20 and a 52 week high of $347.72. The stock has a market cap of $24.22 billion, a PE ratio of 35.71, a P/E/G ratio of 1.32 and a beta of 1.22. The company’s fifty day moving average price is $308.65 and its two-hundred day moving average price is $315.07. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same period in the prior year, the business posted $2.96 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. On average, analysts predict that ICON Public Limited will post 14.54 earnings per share for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.